SCI Pharmtech Inc is a Taiwan-based company mainly engaged in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), API intermediates, and specialty and precision chemicals. The Company's main product categories are APIs, API intermediates, and specialty chemicals. The Company primarily sells its products in Europe, Asia, the Americas, and other domestic and international markets.

Employees

239

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	NT$51.90	+5.60%	685,941
26-07-23	NT$49.15	-1.31%	185,955
26-07-22	NT$49.80	+2.89%	331,304
26-07-21	NT$48.40	+3.64%	288,783
26-07-20	NT$46.70	+0.76%	133,577

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 2026-07-24			5-day change	1st Jan Change
51.90 ^TWD	+5.60%		+11.97%	+6.57%

05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	6.2B 192M 168M 157M 144M 270M 18.46B 274M 1.86B 727M 9.08B 720M 704M 31.39B	P/E 2024	20.3x	P/E 2025	54.2x
Enterprise Value	7.11B 220M 193M 180M 165M 310M 21.18B 315M 2.13B 833M 10.41B 826M 808M 36B	EV / Sales 2024	7.3x	EV / Sales 2025	5.01x
Free-Float	55.34%	Yield 2024	1.66%	Yield 2025	1.54%

05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-05	SCI Pharmtech, Inc. Proposes Dividend Distribution for the Period from January 1, 2025 to December 31, 2025	CI
11-07	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-05	SCI Pharmtech, Inc. Announces Cash Dividend, Payable on August 5, 2025	CI
25-05-26	SCI Pharmtech, Inc. Announces Changes to its Board, Effective May 26, 2025	CI
25-05-08	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-10	Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024	CI
25-03-09	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-09	Sci Pharmtech, Inc. Announces Cash Dividend Payment	CI
24-12-20	Sci Pharmtech, Inc. Announces Appointment of Members of the Sustainable Development Committee	CI
24-11-08	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

22-06-29	SCI Pharmtech : Notice of appointment of general manager of the Board of Directors.	PU
22-06-29	SCI Pharmtech : Notice of the re-election of chairman of the Board of Directors.	PU
22-06-21	SCI Pharmtech : List of the Company's elected directors.	PU
22-06-21	SCI Pharmtech : Notice of the resolutions of 2022 general shareholders' meeting.	PU
22-06-21	SCI Pharmtech : Notice of re-election of functional committees' members	PU

SCI Pharmtech, Inc. Stock

Stocks

4119

TW0004119003

Pharmaceuticals

Valuation: SCI Pharmtech, Inc.

Chart: SCI Pharmtech, Inc.

Latest news : SCI Pharmtech, Inc.

Press Releases: SCI Pharmtech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: SCI Pharmtech, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+5.60%
1 week	+11.97%
Current month	+15.85%
1 month	+17.29%
3 months	+7.56%
6 months	-3.71%
Current year	+6.57%

1 week	46.1	52.1
1 month	43.5	52.1
Current year	39.6	55.5
1 year	39.6	63.2
3 years	39.6	106.5
5 years	39.6	119.56
10 years	39.6	119.56

Manager	Title	Age	Since
Wei Chun Weng CEO	Chief Executive Officer	-	-
Wen Chen Yang DFI	Director of Finance/CFO	-	2002-12-31
Wen Chih Chou PRN	Corporate Officer/Principal	-	2010-08-31

Director	Title	Age	Since
Wei Chun Weng CHM	Chairman	-	2001-12-16
Hsiang Li Chen BRD	Director/Board Member	-	2001-12-16
Wen Chih Chou BRD	Director/Board Member	-	2010-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCI PHARMTECH, INC.	+5.60%	+11.97%	-15.88%	-48.56%	192M
MERCK & CO., INC.	+0.45%	+2.80%	+55.83%	+20.48%	324B
MERCK KGAA	-0.07%	+2.09%	+22.76%	-11.68%	68.88B
HALOZYME THERAPEUTICS, INC.	+1.35%	+5.29%	+39.41%	+91.60%	9.72B
KYOWA KIRIN CO., LTD.	+0.93%	-1.38%	+1.71%	-4.10%	8.37B
SK BIOPHARMACEUTICALS CO., LTD.	+1.13%	+1.51%	-20.98%	-4.73%	4.32B
BETTA PHARMACEUTICALS CO., LTD.	-4.00%	+0.71%	-7.10%	+12.39%	3.62B
YUHAN CORPORATION	+4.90%	+5.79%	-39.25%	+19.34%	3.83B
SUPERNUS PHARMACEUTICALS, INC.	-2.10%	-3.83%	+40.64%	+53.74%	2.68B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-4.07%	-2.45%	-3.76%	-17.52%	2.04B
Average	+0.41%	+2.23%	+7.34%	+11.10%	42.74B
Weighted average by Cap.	+0.37%	+2.18%	+46.49%	+16.09%

	2024	2025
Net sales	1.52B 47.1M 41.37M 38.47M 35.3M 66.33M 4.54B 67.36M 457M 178M 2.23B 177M 173M 7.71B	1.34B 41.54M 36.48M 33.93M 31.13M 58.5M 4B 59.4M 403M 157M 1.97B 156M 153M 6.8B
Net income	535M 16.53M 14.52M 13.5M 12.39M 23.28M 1.59B 23.63M 160M 62.63M 783M 62.05M 60.71M 2.71B	107M 3.32M 2.92M 2.71M 2.49M 4.67M 320M 4.75M 32.19M 12.58M 157M 12.46M 12.19M 543M
Net Debt	298M 9.2M 8.08M 7.51M 6.9M 12.96M 886M 13.16M 89.24M 34.86M 436M 34.54M 33.79M 1.51B	912M 28.2M 24.77M 23.04M 21.14M 39.72M 2.72B 40.33M 274M 107M 1.34B 106M 104M 4.62B